Document:

Exhibit
10.1

 

EXCLUSIVE
LICENSE AGREEMENT

 

This
License Agreement (the “Agreement”) is entered into by and between University of Maryland, Baltimore County, having
an address of 1000 Hilltop Circle, Baltimore, Maryland 21250, a public agency and instrumentality of the State of Maryland (hereinafter
referred to as “UMBC”); and BriaCell Therapeutics Corp., a corporation having its principal place of business at 2929
Arch Street, 3rd Floor, Philadelphia, PA 19104 (hereinafter referred to as “Licensee”).

 

WITNESSETH:

 

WHEREAS,
valuable invention entitled Soluble CD80 as a Therapeutic to Reverse Immune Suppression in Cancer Patients (UMBC Ref. No. 2649SR)
(hereinafter referred to as the “Invention”) was developed during the course of research conducted by Suzanne Ostrand-Rosenberg
(hereinafter, referred to as the “Inventor”); while an employee, student, or postdoctoral fellow of UMBC; and

 

WHEREAS,
UMBC exclusively owns all rights, title and interest in the Inventions and the Patent Rights, with the exception of certain rights retained
by the United States Government; and

 

WHEREAS,
Licensee has submitted a business plan indicating Licensee’s strategies to develop and commercialize the technology and UMBC
has determined, based upon such business plan, that granting a license to its rights in the Invention to Licensee is a benefit to the
public; and

 

WHEREAS,
Licensee desires to obtain a license to use the Invention as herein provided and commits to use commercially reasonable efforts and resources
to commercially develop, manufacture, use and distribute products throughout the Licensed Field; and

 

WHEREAS,
Licensee enters into this Agreement with UMBC, under the terms and conditions set forth herein.

 

NOW,
THEREFORE, in consideration of the mutual covenants and premises contained herein, the receipt and sufficiency of which is hereby acknowledged,
the Parties hereto agree as follows:

 

ARTICLE
1: DEFINITIONS

 

All
references to particular Exhibits and Articles shall mean the Exhibits to, and Articles of, this Agreement, unless otherwise specified.
For the purposes of this Agreement and the Exhibits hereto, the following words and phrases shall have the following meanings:

 

	1.1.1	“Affiliate”
    as used herein in either singular or plural shall mean every entity, corporation, company, partnership, or joint venture, which
    controls, or through one or more intermediaries, is directly or indirectly controlled by, or is under common control with Licensee.
    An entity is deemed to be in control of another corporation or entity if (a) it owns or directly or indirectly controls at least
    50% of the voting stock of the other corporation or (b) in the absence of ownership of at least 50% of the voting stock of a corporation,
    or in the case of a non-corporate entity, if it possesses directly or indirectly, the power to direct or cause the direction of the
    management and policies of such entity or (c) in any country where the local law does not permit foreign equity participation of
    at least fifty percent (50%), then an “Affiliate” includes any company in which Licensee owns or controls or is owned
    or controlled by, directly or indirectly, the maximum percentage of outstanding stock or voting rights permitted by local law.

 

    	1

     

    

 

	1.1.2	“Agreement”
    or “License Agreement” means this Agreement, including all Exhibits attached to this Agreement.
	 	 
	1.1.3	“Assignment”
    means an agreement between Licensee and a third party for the third party to assume the obligations of Licensee under this Agreement
    and to become the master licensee in place of Licensee under this Agreement.
	 	 
	1.1.4	[intentionally
    left blank]
	 	 
	1.1.5	“Commercially
    Reasonable Efforts” means with respect to the commercialization of a Licensed Product, efforts that are consistent with
    those utilized by companies of size and type similar to Licensee (or, if applicable, a Sublicensee), for products with similar commercial
    potential at a similar stage, taking into consideration their cost to develop, the competitiveness of alternative products, the nature
    and extent of their market exclusivity, the likelihood of regulatory approval, their profitability, and all other relevant factors.
	 	 
	1.1.6	“Combination
    Product” means any product comprised of a combination of (a) a Licensed Product (as described below) and (b) any active
    ingredient(s), device(s), delivery system(s) or other technology(ies) for which rights are not included in the license granted under
    this Agreement but, with respect to the items in (b), may each or collectively form the basis for a separately saleable product (“Independent
    Subproduct”)
	 	 
	1.1.7	“Compulsory
    Royalty” shall have the meaning set forth in Article 3.9.
	 	 
	1.1.8	“Confidential
    Information” means any information disclosed by one party to the other party that is identified as confidential at the
    time of disclosure, including information consisting of data; research results; technology; software; materials; patents; copyrighted
    works; know- how; business or product plans; marketing, sales or other financial information; Progress Reports; and Royalty Reports.
	 	 

    	2

     

    

 

			

	1.1.9	“Deferral
    Period” shall mean the period from the Effective Date until the earlier of (i) the sale of all or substantially all of
    the assets of the Licensee (or that portion of its assets related to the subject matter of this Agreement) or (ii) within six (6)
    months following the Effective Date.
	 	 
	1.1.10	“Exchange
    Consideration” shall have the meaning as set forth in Article 3.6.
	 	 
	1.1.11	“Effective
    Date” shall mean the date the last party hereto has executed this Agreement.
	 	 
	1.1.12	“FDA”
    means the United States Food and Drug Administration, or a successor federal agency thereto in the United States.
	 	 
	1.1.13	“First
    Commercial Sale” shall mean the first transfer by a Licensee, Affiliated Company or Sublicensee of a Licensed Product for
    value.
	 	 
	1.1.14	“Independent
    Subproduct” shall have the meaning set forth in Article 1.1.6.
	 	 
	1.1.15	“Improvement”
    shall mean an invention which: (1) is made after the Effective Date; (2) is directly related to the Patent Rights, but is not
    included within the definition of Patent Rights; (3) is or may be patentable or otherwise protected or protectable under law as intellectual
    property; and (4) is not otherwise included in the definition of Licensed Product. For clarity, an invention will ot be a Improvement
    if it is covered by the definition of Licensed Product.
	 	 
	1.1.16	“Licensed
    Field” shall mean the practice of the Patent Rights in all fields.
	 	 
	1.1.17	“Licensed
    Product” as used herein in either singular or plural shall mean: (a) any process or method that is covered in whole or
    in part by a Valid Claim (a “Patent- Based Process”); or (b) any material, composition, device, or other product or product
    part that is covered by a Valid Claim (a “Patent-Based Product”); (c) or is made by using a Patent-Based Process; or
    (d) is employed to practice a Patent- Based Process; the manufacture, use, practice, performance or sale of which would constitute,
    but for the license granted to Licensee pursuant to this Agreement, an infringement of a Valid Claim (infringement shall include,
    but is not limited to, direct, contributory, or inducement to infringe).
	 	 
	1.1.18	“Licensed
    Territory” means worldwide.

 

    	3

     

    

 

	1.1.19	“Net
    Sales” means the total invoiced sales price for Licensed Products sold by Licensee or an Affiliate less (a) sales taxes
    or other taxes (other than income taxes), (b) shipping and insurance charges, (c) actual allowances, rebates, credits, or refunds
    for returned or defective goods, (d) trade, quantity, and other discounts, retroactive price reductions, or other allowances actually
    allowed or granted from the billed amount and taken, (e) rebates, credits, and chargeback payments (or the equivalent thereof) granted
    to managed health care organizations, wholesalers, or to federal, state/provincial, local and other governments, including their
    agencies, purchasers, and/or reimbursers, or to trade customers, and (f) any import or export duties, tariffs, or similar charges
    incurred with respect to the import or export of Licensed Products into or out of any country in the Licensed Territory. Licensed
    Products will be considered sold when paid for. Notwithstanding the foregoing, Net Sales shall not include, and shall be deemed zero
    with respect to, (i) the distribution of reasonable quantities of promotional samples of Licensed Products, (ii) Licensed Products
    provided for research, charitable, or compassionate use purposes, or (iii) Licensed Products provided to a Sublicensee under an agreement
    in which Licensee (or an Affiliate) shall be receiving royalties or other consideration upon which Licensee must pay certain amounts
    to UMBC under Article 3.6, subject to limitation for some specific technologies/circumstances.
	 	 
	 	In
    the case of discounts on “bundles” of separate products or services which include Licensed Products, Licensee or Affiliates
    may discount the bona fide list price of a Licensed Product by the average percentage discount of all products of Licensee and/or
    Affiliates in a particular “bundle”, calculated as follows: Average percentage discount on a particular “bundle”
    = [1 - (X/Y)] x 100 where X equals the total discounted price of a particular “bundle” of products, and Y equals the
    sum of the undiscounted bona fide list prices of each unit of every product in such “bundle”. Licensee (or Affiliates)
    shall provide University documentation reasonably supporting such average discount with respect to each “bundle.” If
    a Licensed Product in a “bundle” is not sold separately, and no bona fide list price exists for such Licensed Product,
    Licensee and University shall negotiate in good faith a reasonable imputed list price for such Licensed Product and Net Sales with
    respect thereto shall be based on such imputed list price.
	 	 
	1.1.20	[intentionally
    left blank]
	 	 
	1.1.21	“Patent
    Rights” shall mean the patent applications attached hereto as “Exhibit A” and the invention disclosed and claimed
    therein owned or controlled by UMBC, and continuing applications thereof including any continuations, continuations-in-part, divisionals,
    provisionals, continued prosecution applications, substitutions, extensions and term restorations, registrations, confirmations,
    re-examinations, renewals, or reissues of any of the foregoing; and any corresponding foreign patent applications, and any patents,
    patents of addition, or other equivalent foreign patent rights issuing, granted or registered thereon. Continuations-in-part shall
    only be included in Patent Rights to the extent UMBC has the right to provide such rights to Licensee.
	 	 
	1.1.22	“Patent
    Costs” are all costs of prosecuting and maintaining any Patent Rights, including attorneys’ fees or costs paid or
    incurred, and expenses paid or incurred for filing, maintenance, annuities, translation, or other costs directly related to prosecution
    and protection.
	 	 

    	4

     

    

 

	1.1.23	“Research
    Collaborators” means Government Agencies, Research Sponsors, Academic institutions, including University System of Maryland.
	 	 
	1.1.24	“Sublicensee”
    as used herein in either singular or plural shall mean any person or entity to which rights are granted by Licensee (or an Affiliate)
    with respect to the Patent Rights. “Sublicensee” shall also include any third party to whom such rights are granted through
    further sublicense by a Sublicensee.
	 	 
	1.1.25	“Sublicensing
    Revenue” means any consideration actually received by Licensee or an Affiliate from a third party as consideration for
    the grant of rights to Patent Rights (net of any tax or similar withholding obligations imposed by any tax or other government authority(ies)
    that are not reasonably recoverable by Licensee). Sublicensing Revenue includes, but is not limited to, upfront fees, license maintenance
    fees, and milestone payments, or other payments, including the fair market value of any non-cash consideration, received by Licensee
    in consideration for any rights granted to Patent Rights under a sublicense agreement, and excludes (i) Sublicensing Royalty Revenue,
    (ii) purchases of equity or debt of Licensee or any Affiliate, (iii) fair market value payments made in connection with research
    and development agreements, joint ventures, partnerships or collaboration agreements where Licensee or an Affiliate is obligated
    to perform research and development of any Licensed Product(s), (iv) the grant to Licensee of intellectual property rights related
    to the technology described in the Patent Rights, and (v) other payments made by a Sublicensee as consideration for Licensee’s
    or an Affiliate’s performance of services or provision of goods, provided such services or goods are not Licensed Products
    or, if such services or goods are Licensed Products, (a) the provision of such services or goods results in Net Sales pursuant to
    which a royalty is payable under Article 3.4 or (b) the provision of such services or goods constitutes one or more of the following:
    (1) the distribution of reasonable quantities of promotional samples of Licensed Products or (2) the provision of Licensed Products
    for research, charitable, or compassionate use purposes.
	 	 
	1.1.26	“Sublicensing
    Royalty Revenue” means sales-based royalties, sales milestone payments, other payments calculated on the basis of sales,
    and minimum sales royalties actually received by Licensee or its Affiliate from a third party as consideration for the grant of rights
    to Patent Rights (net of any tax or similar withholding obligations imposed by any tax or other government authority(ies) that are
    not reasonably recoverable by Licensee).
	 	 
	1.1.27	“Term”
    means the period of time beginning on the Effective Date and ending on the expiration date of the longest-lived Patent Rights.

 

    	5

     

    

 

	1.1.28	“Third
    Party Royalties” means any royalties Licensee owes to one or more third parties pursuant to one or more licenses to intellectual
    property rights entered into by Licensee to avoid infringement of such rights by the practice of the Patent Rights in the manufacture,
    use, or sale of any Licensed Product, or to avoid infringement-related litigation with respect to the practice of the Patent Rights,
    as determined by Licensee in its reasonable discretion.
	 	 
	1.1.29	“Valid
    Claim” means any issued, unexpired or pending claim contained in the Patent Rights that has not been dedicated to the public,
    disclaimed, abandoned or held invalid or unenforceable by a court or other body of competent jurisdiction from which no further appeal
    can be taken, and that has not been explicitly disclaimed, or admitted by University in writing to be invalid or unenforceable or
    of a scope not covering Licensed Products through reissue, disclaimer or otherwise.

 

ARTICLE
2: GRANT OF LICENSE

 

2.1
Grant to Licensee.

 

Subject
to compliance with this Agreement, and subject to receipts of payments, UMBC grants to Licensee and its Affiliates to the extent of the
Licensed Territory an exclusive license under Patent Rights to practice, develop, manufacture, use, make, sell, have made, have sold,
offer for sale and import Licensed Products in the Licensed Field, with the right to sublicense as set forth in Article 2.2, subject
to all the terms and conditions of this Agreement.

 

2.2
Sublicense.

 

2.2.1
The Licensee may sublicense any and all rights licensed hereunder to third parties during the Term of Agreement, but such right is subject
to University’s approval, which shall not be unreasonably withheld. Licensee shall notify in writing and provide UMBC with a copy
of the proposed Sublicense Agreement. Each Sublicense Agreement shall be consistent with the terms and conditions of this Agreement.

 

2.2.2
Licensee is responsible for collecting and guaranteeing payment of all payments due, directly or indirectly, to UMBC from Sublicensee
and summarizing and delivering all reports due, directly or indirectly, to UMBC from Sublicensee. In no case, however, will UMBC be bound
by duties and obligations contained in any Sublicense that extends beyond the duties and obligations of UMBC set forth in this Agreement.

 

2.2.3
If any Sublicensee exercises rights under this Agreement, such shall be bound by all terms and conditions of this Agreement, including
but not limited to indemnity and insurance provisions and royalty payments. In addition, Licensee shall remain fully liable to UMBC for
all acts and obligations of Sublicensee such that acts of the Sublicensee shall be considered acts of the Licensee.

 

    	6

     

    

 

2.2.4
Licensee shall not grant sublicenses to the rights granted hereunder for no consideration or solely in exchange for the grant to Licensee
of intellectual property rights unrelated to the technology described in the Patent Rights, without the prior written consent of the
University. For the avoidance of doubt, the requirements of this Article 2.2.4 forbid Licensee from sublicensing the Patent Rights as
part of a cross-license agreement or as part of a settlement agreement without University’s prior written consent after full disclosure
of the entire transaction contemplated by Licensee that in any way involves the Patent Rights.

 

2.2.5
Licensee and its Sublicensees may grant to a third party a royalty-free sublicense solely for the purpose of conducting research and/or
development activity associated with the use of Licensed Products as may be required by the Food and Drug Administration (FDA) or other
governmental regulatory agency from time to time (collectively “Research Trials”). This grant is limited to the duration
of and activities associated with any Research Trials. University pre-approval is not required for sublicenses of this type.

 

2.3
Reservation of Rights.

 

2.3.1
UMBC retains on behalf of itself and any Research Collaborators the rights to practice under the Patent Rights and to make and use Licensed
Product(s) on a royalty- free basis for its own internal research, public service, scholarly use, patient care incidental to the foregoing,
teaching, training, and educational purposes, including sponsored research and collaborations. UMBC shall require Research Collaborators
to abide by the terms, conditions, and limitations of this Agreement. Subject to the rights of a third party which collaborates on or
sponsors research at UMBC which results in an Improvement, UMBC hereby grants Licensee an exclusive first option to obtain an exclusive
license to UMBC’s rights to any Improvement. Licensee may exercise the option by giving written notice to UMBC wthin 60 days after
Licensee receives written notice from UMBC of the Improvement.

 

2.3.2
UMBC’s use and any Research Collaborator’s use of such reserved rights shall not include any human use or clinical administration
without prior written approval from Licensee, such approval not to be unreasonably withheld.

 

2.3.3
UMBC shall also retain the rights on behalf of itself and any Research Collaborators to disseminate and publish material and scientific
findings from its research related to the Patent Rights(s) and/or Licensed Products, and to permit its personnel to do the same.

 

2.4
No Implied License.

 

Any
right not expressly granted to Licensee under this Agreement is expressly reserved by UMBC. The License and the rights granted in this
Agreement shall not be construed to confer any license or rights upon Licensee by implication, estoppel, or otherwise to any intellectual
property, research, development, data, results or technology, including any patent, patent application, trademark, trademark application,
copyright, know-how, tangible research property or other proprietary right, in whole or in part, not specifically and expressly stated
in this Agreement.

 

    	7

     

    

 

2.5
Government Rights and Requirements

 

The
Patent Rights licensed under this Agreement may have been developed with financial or other assistance provided by the United States
government. Under the provisions of 35 U.S.C. §§ 200-212 and applicable regulations of Title 37 of the Code of Federal
Regulations, The United States Government is entitled, as a right: (i) to a nonexclusive, nontransferable, irrevocable, paid-up
license to practice or have practiced for or on the behalf of the United States Government any of the Patent Rights throughout the
world and (ii) to exercise march in rights on Patent Rights.

 

2.6
Manufacturing in the United States.

 

Licensee
agrees to be bound by the provisions of 35 U.S.C. § 204; accordingly Licensee agrees that Licensed Products sold in the United States
and subject to government rights shall be substantially manufactured in the United States. UMBC agrees to assist Licensee in requesting
a waiver of this requirement from the appropriate funding agency, if one is needed.

 

2.7
Patent Acknowledgement.

 

Licensee
agrees that all packaging containing individual Licensed Products sold by Licensee and Sublicensee(s) will be marked with the number
of the applicable patent(s) licensed hereunder in accordance with and as permitted by each country’s patent laws.

 

2.8
Export Controls.

 

In
accordance with Federal Export Laws, Licensee shall be responsible for taking any steps necessary to comply with the export, assets,
and financial control regulations of the United States of America. Exports of Licensed Products may be subject to U.S. export control
laws and regulations, including, without limitation, the Export Administration Regulations (15 CFR 730-774) and the International Traffic
in Arms Regulations (22 CFR 120-130), and may be subject to export or import regulations in countries other than the United States. Licensee
assumes all obligations and responsibility for assuring that use of the Licensed Products is in compliance with all applicable export
control laws and regulations. Further, Licensee agrees to require Sublicensees to comply with said obligations and responsibility.

 

    	8

     

    

 

ARTICLE
3: CONSIDERATION

 

3.1
License Issue Fee.

 

Waived.

 

3.2
Reimbursement of Past Patent Costs.

 

Licensee
shall reimburse UMBC for all documented Patent Costs incurred prior to the Effective Date, and associated with the preparation, filing,
prosecuting, issuance and maintenance of all patent applications and patents included within the Patent Rights, that are not to exceed
twenty-two thousand, four hundred and forty-nine dollars and thirty cents ($ 22,449.30) (“Past Patent Costs”). See Exhibit
D for documentation.

 

During
the Deferral Period UMBC agrees to postpone collection of the Past Patent Costs. Once the Deferral Period has ended, payment will be
due within thirty (30) days of receiving an invoice from UMBC.

 

3.3
Reimbursement of Ongoing Patent Costs.

 

Licensee
shall reimburse UMBC for Patent Costs incurred on or after the Effective Date, within thirty (30) days of receiving an invoice from UMBC.
Responsibilities for patent prosecution and maintenance are outlined in Article 5.

 

3.4
Earned Royalty.

 

Beginning
on the Effective Date and continuing for the life of this Agreement, Licensee shall pay UMBC a running royalty on Net Sales of all Licensed
Products in the amount indicated below:

 

(i)
two percent (2%) on Net Sales of all Licensed Products.

 

Said
royalties on Licensed Products shall be paid to UMBC concurrently with the submittal of Royalty Reports as provided in Article 4.3 below.

 

3.5
Annual License Maintenance Fee.

 

Licensee
shall pay an Annual License Maintenance Fee to UMBC in the amount indicated in the Schedule below.

 

Annual
License Maintenance Fee Schedule

 

	Years	 	Date Due	 	Amount	 
	Beginning with the 5th calendar year following the Effective Date through
    the 7th calendar year following the Effective Date	 	Each March 15th beginning on March 15, 2027 and continuing through
    March 15, 2029	 	$	15,000	 
	Beginning with the 8th calendar year following the Effective Date and each calendar
    year thereafter	 	Each March 15th beginning on March 15, 2030 and continuing throughout the term
    of this Agreement	 	$	30,000	 

 

    	9

     

    

 

The
aforementioned Annual License Maintenance Fees shall be paid to UMBC on the dates set forth in the above table. Subsequent to the First
Commercial Sale of a Licensed Product, the aforementioned Annual License Maintenance Fees shall be creditable against (Earned Royalty)
Article 3.4, (Sublicensing Revenue) Article 3.6(i), and (Sublicensing Royalty Revenue) Article 3.6(ii) in the previous calendar year.

 

3.6
Sublicense Fees.

 

In
respect to sublicenses granted by Licensee under Article 2.2, (i) Licensee shall pay to UMBC an amount equal to twenty-five percent (25%)
of Sublicensing Revenue. Any such payment shall be made within thirty (30) days of Licensee’s receipt of Sublicensing Revenue;
and (ii) Licensee shall pay to UMBC an amount equal to fifty percent (50%) of Sublicensing Royalty Revenue provided that, notwithstanding
the foregoing, the total payment due UMBC under this Article 3.6(ii) with respect to Sublicensing Royalty Revenue received from a Sublicensee
during any particular time period shall not, in any event, exceed an amount equal to the royalties that would have been due to UMBC with
respect to the Licensed Products sold by such Sublicensee generating such Sublicensing Royalty Revenue had Licensee itself sold such
Licensed Products, based on such Sublicensee’s net sales of such Licensed Products (determined in a manner substantially similar
to the manner in which Net Sales are determined under this Agreement for Licensee’s sales of Licensed Products) and calculated
in a manner consistent with Articles 3.4, 3.7, 3.8, and 3.9. Any such payments shall be made concurrently with the submission of Royalty
Reports as set forth in Article 4.3.

 

Licensee
shall not sell or transfer to a third party Licensee’s interest in all or a portion of any future Sublicensing Revenue and/or Sublicensing
Royalty Revenue under such sublicense agreement(s) in exchange for a single cash payment or series of cash payments (the “Exchange
Consideration”) without the prior written approval of UMBC, such approval not to be unreasonably withheld. In the event that UMBC
approves such sale or transfer, (a) the portion of any Exchange Consideration reasonably allocated by Licensee to the value of its interest
in such future Sublicensing Revenue shall be treated as Sublicensing Revenue for purposes of this Article 3.6 and (b) the portion of
any such Exchange Consideration reasonably allocated by Licensee to the value of its interest in such future Sublicensing Royalty Revenue
shall be treated as Sublicensing Royalty Revenue for purposes of this Article 3.6. If any portion of the Exchange Consideration has been
allocated to the value of Licensee’s interest in future Sublicensing Revenue or Sublicensing Royalty Revenue, any such Sublicensing
Revenue or Sublicensing Royalty Revenue shall thereafter not be included within the definitions of Sublicensing Revenue or Sublicensing
Royalty Revenue originally established in Article 1.

 

    	10

     

    

 

3.7
Royalty Stacking.

 

In
the event that Licensee is required to pay Third Party Royalties, then Licensee may deduct an amount equal to fifty percent (50%) of
any Third Party Royalties from any royalty amounts due UMBC hereunder, provided that in no event shall the royalties otherwise due UMBC
be less than fifty percent (50%) of the royalties that would be payable to UMBC absent the effects of this Article 3.7. In the event
that UMBC does not own all right, title, and interest in the Patent Rights, and Licensee obtains, by license(s), assignment(s), or otherwise,
rights to any third party(ies)’ interest(s) in such patent applications or patents, any amounts paid by Licensee to such third
party(ies) to obtain any rights in any third party interest(s) in such Patent Rights shall be treated as Third Party Royalties.

 

3.8
Combination Product.

 

If
a Licensed Product is sold as part of a Combination Product, Net Sales shall be calculated by multiplying Net Sales for such Combination
Product by the fraction A/(A+B) where A is the invoice price of the Licensed Product when sold separately, and B is the aggregate invoice
price of the Independent Subproduct(s) in the combination when sold separately. If either the Licensed Product or the Independent Subproduct(s)
is(are) not at that time sold separately, than the allocation of Net Sales shall be commercially reasonable and determined by good faith
negotiation between UMBC and Licensee, based on the relative value of the Licensed Product and Independent Subproduct(s), consistent
with the formula provided above.

 

3.9
Compulsory Licensing.

 

Should
a compulsory license be granted, or be the subject of a possible grant, by Licensee or an Affiliate to a third party under the applicable
laws, rules, regulations, guidelines, or other directives of any governmental or supranational agency in the Licensed Territory under
the Patent Rights, Licensee shall notify UMBC, including any material information concerning such compulsory license, and the running
royalty rates payable under Section 3.4 for sales of Licensed Products in such country will be adjusted to equal any lower royalty rate
granted to such third party for such country with respect to the sales of such Licensed Products therein (the “Compulsory Royalty”).

 

3.10
Payment.

 

All
fees, royalties, and other payments due to UMBC under this Agreement shall be made in United States Dollars. If any currency conversion
shall be required in connection with the payment of royalties hereunder, such conversion shall be made using the exchange rate published
in the Wall Street Journal on the last business day of the calendar quarterly reporting period to which such royalty payments relate.

 

If
payments are made by check, check shall be drawn on a United States bank and shall be made payable to “The University of Maryland,
Baltimore County” and sent to “Director” at the mailing address pursuant to Article 12.5 and reference Agreement No.
2022-0033.

 

    	11

     

    

 

If
Licensee is not able to pay by check and therefor elects to make payments by wire, Licensee will pay all fees associated with processing
the wired payments and will follow the wire instruction provided on invoices from UMBC.

 

ARTICLE
4. RECORDS AND REPORTS

 

4.1
Records of Sales.

 

4.1.1
During the Term of this Agreement and for a period of three (3) years thereafter, Licensee shall keep at its principal place of business
true and accurate records of all information relating to data reasonably required for the full computation and verification of sales
to gross receipts, unit royalties, verification of Licensee’s calculation of amounts payable to UMBC under this Agreement, and
files and books of account containing all the data reasonably required for the full computation and verification of sales and other information
required in Article 3.

 

4.1.2
Such books and records shall be in accordance with generally accepted accounting principles consistently applied. Licensee shall permit
the inspection and copying of such records, files and books of account by UMBC or its agents during regular business hours upon ten (10)
business days’ written notice to Licensee. Such inspection shall not be made more than once each calendar year. All costs of such
inspection and copying shall be paid by UMBC, provided that if any such inspection shall reveal an error has been made in the amount
equal to five percent (5%) or more of such payment, such costs shall be borne by Licensee. Licensee shall include in any agreement with
its Affiliated Companies or its Sublicensees which permits such party to make, use or sell Licensed Products, a provision requiring such
party to retain records of sales of Licensed Products and other information as required in Article 4.1.1 and to permit UMBC to inspect
such records as required by this Article.

 

4.2
Progress Report

 

4.2.1
A Progress Report will be due annually. Licensee shall submit the first Progress Report March 15, 2023, and shall submit a Progress Report
on March 15 every year thereafter until all outstanding milestone events have been attained.

 

4.2.2
A Progress report shall include a summary of work completed, summary of work in progress, current Exhibit of anticipated events or milestones,
market plans for introduction of Licensed Products, key management changes, number of employees, summary of any payments due under Article
3, and Licensee’s finances which may materially impact Licensee’s ability to develop Licensed Products.

 

    	12

     

    

 

4.2.3
Progress Reports submitted when no payment is due under Article 3.5 may be sent as an attachment to UMBC’S email address: [otd@umbc.edu]
and should be marked with the following title “Progress Report <Licensee Name> UMBC Agreement ref. 2022- 0033.”

 

4.2.4
In addition to submitting written Progress Reports, Licensee agrees to be available for periodic (no more often than monthly) meetings
or teleconferences to update UMBC on Licensee’s progress to develop and commercialize Licensed Products. The meetings or teleconferences
will be held at times mutually agreeable to both parties.

 

4.3
Royalty Report

 

4.3.1
Following the First Commercial Sale of a Licensed Product anywhere in the world, Licensee shall submit to UMBC semi annual royalty reports
within thirty (30) days of the end of every June and December.

 

Each
Royalty Report shall cover Licensee’s, and each Affiliate’s and Sublicensee’s most recently completed calendar biannual
period and shall show:

 

	 	(1)	The
    amount of Licensed Products sold;
	 	(2)	The
    total Net Sales of such Licensed Products;
	 	(3)	The
    running royalties due to UMBC as a result of Net Sales by License, Affiliated Companies, and Sublicensees;
	 	(4)	The
    method used to calculate the royalties (including the Exchange Rate used as required by Article 3; and
	 	(5)	Payment
    as outlined in Article 3.10, of any such royalties due shall accompany such report.

 

4.3.2
Licensee shall report if no sales of Licensed Products have been made and Licensee has received no Sublicense Revenue during any reporting
period.

 

4.3.3
Royalty Reports submitted when no payment is due may be sent as an attachment to UMBC’S email address: [otd@umbc.edu] and should
be marked with the following title “Royalty Report <Licensee Name> UMBC Agreement ref. 2022-0033.”

 

ARTICLE
5. PATENT PROSECUTION

 

5.1
Prosecution and Maintenance of Patent Rights.

 

5.1.1
UMBC shall be solely responsible for the prosecution and maintenance of all patents and patent applications specified under Patent Rights.
Patent filings and prosecution shall be by counsel of UMBC’s choosing and shall be in the name of UMBC. UMBC shall keep Licensee
informed as to all material developments and costs with respect to the filing, prosecution and maintenance of Licensed Patent(s) and
Licensee shall keep this information confidential. Prosecution includes, but is not limited to; interferences, oppositions and any other
inter partes matters originating in a patent office.

 

    	13

     

    

 

5.1.2
Provided Licensee is in compliance with the terms of this Agreement, UMBC shall provide Licensee a reasonable opportunity, to comment
and advise on patent prosecution and maintenance matters. However, UMBC shall have the right to make the final decisions for all matters
associated with such prosecution and maintenance. Failure to provide authorization at least thirty (30) days before an action is due
can be considered by UMBC as a Licensee decision not to authorize an action.

 

5.2.
Foreign Patent Applications.

 

5.2.1
With respect to prosecution and maintenance of foreign patent applications corresponding to the U.S. Patent applications described in
Exhibit A, Licensee shall notify UMBC in writing which country or countries, if any, in which Licensee desires such corresponding patent
application(s) to be filed.

 

5.2.2
UMBC will file and prosecute a patent application in any country requested by Licensee as long as (i) Licensee is not in default of any
obligations under this Agreement as of the date written notice is received by UMBC; (ii) Licensee’s written notification to UMBC
is received at least thirty (30) days in advance of any filing or response deadline, or fee due date; and (iii) Licensee is in compliance
with the terms and conditions of this Agreement.

 

5.3
Election not to file.

 

5.3.1
Licensee may elect not to have a patent application filed or not to pay expenses associated with prosecuting or maintaining any patent
application or patent, by written notification to UMBC at least thirty (30) days in advance of any filing or response deadline, or fee
due date.

 

5.3.2
UMBC shall use reasonable efforts to curtail further Patent Costs for such application or patent when such notice of termination is received
from Licensee. However, Licensee shall reimburse UMBC for all costs incurred up to UMBC’s receipt of such notification. UMBC, in
its sole discretion and at its sole expense, may continue prosecution and maintenance of said application or patent, and Licensee shall
have no further license with respect thereto. Non-payment of any portion of Patent Costs due with respect to any application or patent
may be deemed by UMBC as an election by Licensee to terminate its reimbursement obligations with respect to such application or patent.
UMBC is not obligated at any time to file, prosecute, or maintain Patent Rights in a country, where, for that country’s patent
application Licensee is not paying Patent Costs, or to file, prosecute, or maintain Patent Rights to which Licensee has terminated its
license hereunder.

 

    	14

     

    

 

ARTICLE
6. DUE DILIGENCE

 

6.1
Diligence and Commercialization.

 

6.1.1
Licensee and UMBC shall negotiate in good faith the achievement of any stated milestones by the dates or timelines outlined or established
in the performance milestones as set forth in Exhibit B. The acts of Affiliates, Sublicensee(s), and third party contractors shall be
deemed the acts of Licensee for purposes of satisfying this Article.

 

6.1.2
Licensee shall promptly notify UMBC of any substantial changes, which will materially alter or affect the timely achievement of any milestone
set forth in Exhibit B. Any amendment in the performance milestones that will materially alter or affect the timely achievement of any
milestone, shall require the consent and approval of UMBC, which shall not be unreasonably withheld. Licensee and UMBC shall negotiate
in good faith the performance milestones in Exhibit B.

 

6.1.3
UMBC’s remedy with respect to Licensee’s breach of this Article or failure to achieve the above-referenced milestones shall
be its right to terminate this Agreement in accordance with Article 11. Upon termination of this Agreement, UMBC at its discretion may
grant Licensee a non-exclusive license under terms mutually acceptable to UMBC and Licensee.

 

6.1.4
Licensee has delivered to UMBC prior to execution of this Agreement a business plan, in form and substance reasonably acceptable to UMBC.
A true and complete copy of the business plan is attached hereto as Exhibit C (the “Business Plan”). The Business Plan sets
forth the Licensee’s plan for research and development required in order to develop Licensed Product(s), Licensee’s commercialization
strategy regarding Licensed Product(s), the identified and committed management team of Licensee, and the capitalization plan for Licensee
indicating sufficient access to capital to enable the Business Plan to be executed.

 

ARTICLE
7. ABATEMENT OF INFRINGEMENT

 

7.1
Notice of Infringement.

 

Each
party will notify the other promptly in writing when any infringement by a third party is uncovered or suspected.

 

7.2
Infringement by third party.

 

In
the event any rights specified under Patent Rights are infringed by a third party, Licensee, at its own expense, shall have the first
right, but not obligation, to notify a third party and/or to initiate legal proceedings against third party. UMBC shall reasonably cooperate
in any such litigation at Licensee’s expense. Licensee may not join UMBC in a suit initiated by Licensee without UMBC’s prior
written consent. If, in a suit initiated by Licensee, UMBC is involuntarily joined other than by Licensee, Licensee will pay any costs
incurred by UMBC arising out of such suit, including but not limited to, any legal fees of counsel UMBC selects, and retains to represent
it in the suit.

 

    	15

     

    

 

7.3
Dispute Resolution.

 

7.3.1
Licensee shall be free to enter into a settlement, consent judgment, or other voluntary disposition with respect to any such action,
provided that any settlement, consent judgment or other voluntary disposition thereof which (i) materially limits the scope, validity,
or enforceability of patents included in the Patent Rights or (ii) admits fault or wrongdoing on the part of UMBC must be approved by
UMBC, such approval not to be unreasonably withheld.

 

7.3.2
Licensee’s request for such approval shall include complete copies of final settlement documents, a detailed summary of such settlement,
and any other information material to such settlement. UMBC shall provide Licensee notice of its approval or denial within fifteen (15)
business days of any request for such approval by Licensee, provided that (i) in the event UMBC wishes to deny such approval, such notice
shall include a detailed written description of UMBC’s reasonable objections to the proposed settlement, consent judgment, or other
voluntary disposition and (ii) UMBC shall be deemed to have approved of such proposed settlement, consent judgment, or other voluntary
disposition in the event it fails to provide such notice within such fifteen (15) day period in accordance herewith.

 

7.4
Monetary damages and litigation proceedings.

 

7.4.1
If Licensee recovers monetary damages in the form of lost profits from a third party infringer as a remedy for the infringement of Patent
Rights licensed hereunder, then Licensee shall first apply such recovery to the costs and expenses incurred in obtaining or negotiating
for such recovery (including attorneys’ fees), and pay to UMBC the royalties on the remaining portion of such lost profits at the
rate specified in Article 3. If Licensee recovers monetary damages in the form of a reasonable royalty as a remedy for the infringement
of Patent Rights, then, after applying such royalty to the recovery of the costs and expenses incurred in obtaining or negotiating for
such royalty (including attorneys’ fees), the remaining amount of any such royalty shall be treated as Sublicensing Royalty Revenue
in accordance with Article 3.6.

 

7.4.2
If Licensee elects not to enforce any patent within the Patent Rights, then it shall so notify UMBC in writing within ninety (90) days
of receiving notice that an infringement exists, and UMBC may, in its sole judgment and at its own expense, take steps to enforce any
patent and control, settle, and defend such suit in a manner consistent with the terms and provisions hereof, and recover, for its own
account, any damages, awards or settlements resulting therefrom. In the event, UMBC institutes such suit, Licensee may not join such
suit without UMBC’s consent and may not thereafter commence suit against the infringer for the acts of infringement that are the
subject of UMBC’s suit or any judgment rendered in that suit. If UMBC leads proceedings to abate and remedy infringement, any monetary
recovery from the infringement of Licensed Patents shall belong exclusively to UMBC.

 

    	16

     

    

 

7.4.3
The party bringing the suit will control any litigation proceedings, except that UMBC may be represented by counsel of its choice in
any suit brought by Licensee.

 

7.4.4
If any third party claims patent infringement against Licensee, as a result of Licensee’s use of the Patent Rights, then Licensee
shall promptly notify UMBC thereof in writing, setting forth the facts of such claim in reasonable detail. As between the parties to
this Agreement, Licensee shall have the first and primary right and responsibility at its own expense to defend and control the defense
of any such claim against Licensee, by counsel of its own choice. Licensee shall be free to enter into a settlement, consent judgment,
or other voluntary disposition of any such claim, provided that any settlement, consent judgment or other voluntary disposition of any
such claim that (i) materially limits the scope, validity, or enforceability of patents included in the Patent Rights or (ii) admits
fault or wrongdoing on the part of UMBC must be approved by UMBC, such approval not being unreasonably withheld. Licensee’s request
for such approval shall include complete copies of final settlement documents, a detailed summary of such settlement, and any other information
material to such settlement. UMBC shall provide Licensee notice of its approval or denial within fifteen (15) business days of any request
for such approval by Licensee, provided that (i) in the event UMBC wishes to deny such approval, such notice shall include a detailed
written description of UMBC’s reasonable objections to the proposed settlement, consent judgment, or other voluntary disposition
and (ii) UMBC shall be deemed to have approved of such proposed settlement, consent judgment, or other voluntary disposition in the event
it fails to provide such notice within such fifteen (15) day period in accordance herewith. Any amounts paid to any third party as damages
or other compensation with respect to infringement of a third party’s rights shall be treated as third party royalties that Licensee
shall be entitled to deduct from royalties due UMBC in accordance with Article 3. Licensee shall reimburse UMBC for any reasonable, documented
out of pocket expenses incurred in providing such assistance.

 

ARTICLE
8. REPRESENTATIONS

 

8.1
Representations by UMBC.

 

UMBC
represents that, to the best of its knowledge, as of the Effective Date; (i) UMBC has good and marketable title to its interests in the
inventions claimed in the Patent Rights with the exception of certain rights of the U.S. Government, if any, and (ii) UMBC has not received
any notification, and does not possess any information reasonably indicating, that the Patent Rights are invalid or that the exercise
by Licensee of the rights granted hereunder will infringe on any patent or other proprietary right of any third party.

 

    	17

     

    

 

8.2
Exclusion of Warranties.

 

8.2.1
UMBC makes no representation or warranties;

 

	 	(1)	As
    to any material, or information provided by UMBC in connection with this Agreement, nor does UMBC warrant that the foregoing are
    free of error or defect.
	 	(2)	That
    any patent will issue on the Invention, or
	 	(3)	To
    either defend any infringement charge by a third party or to institute action against infringers of Patent Rights.

 

8.2.2
EXCEPT AS EXPRESSLY SET FORTH IN THIS AGREEMENT, THE INTELLECTUAL PROPERTY LICENSED HEREUNDER IS PROVIDED “AS IS.” UMBC MAKES
NO REPRESENTATION OR WARRANTY WITH RESPECT TO THE PERFORMANCE OF LICENSED PRODUCTS INCLUDING THEIR SAFETY, EFFECTIVENESS, OR COMMERCIAL
VIABILITY. UMBC MAKES NO REPRESENTATION AS TO THE VALIDITY OF THE PATENT RIGHTS OR THAT ANY PRACTICE UNDER THE PATENT RIGHTS SHALL BE
FREE OF INFRINGEMENT OF ANOTHER PATENT OR OTHER PROPRIETARY RIGHT NOT GRANTED TO LICENSEE HEREUNDER. UMBC DISCLAIMS ALL WARRANTIES WITH
REGARD TO PRODUCTS AND SERVICES LICENSED UNDER THIS AGREEMENT, INCLUDING, BUT NOT LIMITED TO, ALL WARRANTIES, EXPRESS OR IMPLIED, OF
MERCHANTABILITY AND FITNESS FOR ANY PARTICULAR PURPOSE. NOTWITHSTANDING ANY OTHER PROVISION OF THIS AGREEMENT, UMBC ADDITIONALLY DISCLAIMS
ALL OBLIGATIONS AND LIABILITIES ON THE PART OF UMBC AND INVENTORS, FOR DAMAGES, INCLUDING, BUT NOT LIMITED TO, DIRECT, INDIRECT, SPECIAL,
AND CONSEQUENTIAL DAMAGES, ATTORNEYS’ AND EXPERTS’ FEES, AND COURT COSTS (EVEN IF UMBC HAS BEEN ADVISED OF THE POSSIBILITY
OF SUCH DAMAGES, FEES OR COSTS), ARISING OUT OF OR IN CONNECTION WITH THE MANUFACTURE, USE, OR SALE OF THE PRODUCT AND SERVICE LICENSED
UNDER THIS AGREEMENT. LICENSEE, AFFILIATED COMPANIES AND SUBLICENSEES ASSUME ALL RESPONSIBILITY AND LIABILITY FOR LOSS OR DAMAGE CAUSED
BY A PRODUCT AND SERVICE MANUFACTURED, USED, OR SOLD BY LICENSEE, ITS SUBLICENSEES AND AFFILIATED COMPANIES WHICH IS A LICENSED PRODUCT
AS DEFINED IN THIS AGREEMENT.

 

ARTICLE
9. INDEMNIFICATION AND LIABILITY

 

9.1
Indemnification.

 

9.1.1
Licensee agrees, and will require Sublicensee to agree to, indemnify, hold harmless and defend UMBC, The University System of Maryland,
the State of Maryland, their present and former trustees, officers, Inventors, agents, faculty, employees and students, as applicable,
against any and all claims, any judgments, fees, expenses, or other costs arising from or incidental to any product liability or other
lawsuit, claim, demand or other action brought as a consequence of the practice of said inventions by any of the foregoing entities,
whether or not UMBC or said Inventors, either jointly or severally, is named as a party defendant in any such lawsuit.

 

    	18

     

    

 

9.1.2
The obligation of Licensee, Sublicensee, or Affiliated Company to defend, indemnify, and hold harmless, as set forth in this Article,
shall survive the termination of this Agreement. This indemnification obligation shall include, without limiting the generality of the
foregoing, reasonable attorney fees and other costs or expenses incurred by Indemnities in connection with the defense of any and all
such claims, demands, actions, or causes of action.

 

9.1.3
Licensee is required to maintain in force at its sole cost and expense, with reputable insurance companies, general liability insurance
and products liability insurance coverage in an amount reasonably sufficient to protect against liability.

 

9.2
Product Liability.

 

As
of the Effective Date, Licensee will have procured and will maintain in full force and effect commercial general liability insurance
policies with coverage amounts of no less than $1,000,000 per incident and $1,000,000 in annual aggregate. Prior to initial human testing
or First Commercial Sale of any Licensed Product, as the case may be, in any particular country, Licensee shall establish and maintain,
in each country in which Licensee, an Affiliated Company or a Sublicensee shall test or sell a Licensed Product, product liability or
other appropriate insurance coverage appropriate to the risks involved in marketing Licensed Products; provided however, such insurance
shall include coverage of at least five million dollars ($5,000,000) per incident. Upon UMBC’s request, Licensee will furnish UMBC
with a Certificate of Insurance for each product liability insurance policy obtained. If such product liability insurance is underwritten
on a ‘claims made’ basis, Licensee agrees that any change in underwriters during the term of this Agreement will require
the purchase of ‘prior acts’ coverage to ensure that coverage will be continuous throughout the term of this Agreement.

 

ARTICLE
10. CONFIDENTIALITY

 

10.1
Agreement Terms.

 

10.1.1
If necessary, the parties will exchange information they consider to be confidential. The sender may mark Confidential Information, as
CONFIDENTIAL, but such designation is not required. Confidential Information, includes but is not limited to information disclosed pertaining
to the financial terms set forth in this Agreement, Technical and Patent related Information disclosed in any pending patent applications
or any other information pertaining to the Patent Rights.

 

    	19

     

    

 

10.1.2
The recipient of such information agrees to treat such information with the same degree of care as it treats its own Confidential Information,
which shall be no less than reasonable, to employ all reasonable efforts to maintain the information secret and confidential, and not
to disclose such information, without the express prior written consent of the sending party.

 

10.1.3
The recipient of such information agrees to accept the disclosure of said information which is marked as confidential at the time it
is sent to the recipient, and to employ all reasonable efforts to maintain the information secret and confidential, such efforts to be
no less than the degree of care employed by the recipient to preserve and safeguard its own confidential information. The information
shall not be disclosed or revealed to anyone except employees of the recipient who have a need to know the information and who have an
obligation to maintain confidential the proprietary information of the recipient. The recipient of the confidential information shall
advise such employees of the confidential nature of the information, and the information shall be treated accordingly.

 

10.1.4
Notwithstanding any other provisions of this Agreement, disclosure by a recipient party of the other party’s Confidential Information
shall not be precluded if such disclosure is in response to a subpoena or other court order. In such case, disclosing party shall make
reasonable provisions for the protection of confidential information and give notice to the other party to permit it to seek a protective
order or grant confidentiality.

 

10.2
Limits on Confidential Information.

 

Confidential
information under this Agreement shall not include information which:

 

	 	(i)	Is
    in the public domain or publicly known prior to the date of the disclosure; or
	 	(ii)	Recipient
    can demonstrate through documentation to have been within recipients’ legitimate possession prior to the time of disclosure
    of such Information to recipient by discloser; or
	 	(iii)	Is
    disclosed to recipient by a third party having legitimate possession of the information and the unrestricted right to make such disclosure,
    as evidenced by written documentation; or
	 	(iv)	Becomes
    publicly known not due to any unauthorized act by the recipient.

 

The
obligations of this Paragraph shall extend until five (5) years after the date of disclosure of the Confidential Information, and apply
to Affiliated Companies and Sublicensee(s).

 

10.3
Right to Publish.

 

UMBC
may publish manuscripts, abstracts or the like describing the Patent Rights and inventions contained therein provided confidential information
of Licensee as defined in Article 10.1.1, is not included or without the express prior written consent of Licensee to include such confidential
information. Otherwise, UMBC and the Inventors shall be free to publish manuscripts and abstracts or the like directed to the research
related to the Patent Rights without Licensee’s prior approval.

 

    	20

     

    

 

ARTICLE
11. TERM AND TERMINATION

 

11.1
Term.

 

The
term of this Agreement shall commence on the Effective Date and shall continue, in each country, until the date of the expiration of
the last to expire Valid Claim included in the Patent Rights or covering a particular Licensed Product in a particular country.

 

11.2
Termination by UMBC.

 

11.2.1
At any time after two (2) years from the Effective Date, if Licensee, either directly or through its Affiliate(s) or Sublicensee(s) fails
to show it has initiated and actively pursued the development and commercialization of Licensed Product as specified in Exhibit B then
UMBC shall have the right and option to either terminate this Agreement or convert Licensee’s exclusive license to a nonexclusive
license.

 

11.2.2
A material breach by Licensee of this Agreement includes Licensee’s failure:

 

	 	(i)	To deliver to UMBC any payment
  at the time or times that such payment is due to UMBC under this Agreement;
	 	(ii)	To provide Royalty Reports
  and Progress Reports as set forth in Article 4;
	 	(iii)	To meet or achieve performance
  milestones as set forth in Exhibit B; and,
	 	(iv)	In the event it executes
  a Sublicense, to execute a Sublicense that comports with terms and conditions outlined in Article 2.2.

 

11.3
Termination by Licensee.

 

Notwithstanding
termination pursuant to Article 11.4, Licensee may terminate this Agreement and the license granted herein, for any reason, upon giving
UMBC sixty (60) days written notice.

 

11.4
Breach of Agreement.

 

Notwithstanding
the provisions of any other paragraph of this Agreement to the contrary, if either party fails to perform or otherwise breaches any of
its obligations hereunder, and fails to cure any such breach within sixty (60) days of receipt of written notice from terminating party
describing such breach, then terminating party has the right to terminate the Agreement.

 

    	21

     

    

 

11.5
Obligations and Duties upon Termination.

 

If
this Agreement is terminated, both parties shall be released from all obligations and duties imposed or assumed hereunder to the extent
so terminated, except as expressly provided to the contrary in this Agreement. Upon termination, both parties shall cease any further
use of the Confidential Information disclosed to the receiving party by the other party. Termination of this Agreement, for whatever
reason, shall not affect the obligation of either party to make any payments for which it is liable prior to or upon such termination.
Termination shall not relieve Licensee of its obligation to pay any royalty or other fees or costs due to UMBC at the time of termination.
Upon termination Licensee shall submit a final royalty report to UMBC and any royalty payments and unreimbursed patent expenses due UMBC
shall become immediately due and payable. Furthermore, upon termination of this Agreement, all rights in and to the Patent Rights shall
revert immediately to UMBC at no cost to UMBC. Upon termination of this Agreement, each Sublicensee, if any, shall be granted the opportunity
to become a direct Licensee of UMBC under terms mutually acceptable to UMBC and the Sublicensee. In the event of the Termination of this
Agreement, Licensee shall provide written notice of such termination, notice of the termination of any sublicense agreement, and notice
of the Sublicense’s right to negotiate a license directly with UMBC to each Sublicensee with a copy of such notice provided to
UMBC.

 

ARTICLE
12. MISCELLANEOUS

 

12.1
Use of Name.

 

Licensee
shall not use the name of UMBC or The University System of Maryland or any of its constituent parts, or any contraction thereof or the
name of the Inventors in any advertising, promotional, sales literature or fundraising documents without prior written notice to UMBC.
Licensee shall allow at least seven (7) business days notice of any proposed public disclosure for UMBC’s review and comment. Licensee
agrees that UMBC may disclose the name of Licensee in publications. Licensee and UMBC agree that they will jointly make an announcement
about the existence of this Agreement.

 

12.2
No Partnership.

 

Nothing
in this Agreement shall be construed to create any agency, employment, partnership, joint venture or similar relationship between the
parties other than that of a licensor/licensee. Neither party shall have any right or authority whatsoever to incur any liability or
obligation (express or implied) or otherwise act in any manner in the name or on the behalf of the other, or to make any promise, warranty
or representation binding on the other.

 

12.3
Notice of claim.

 

Each
party shall give the other or its representative immediate notice of any suit or action filed, or prompt notice of any claim made, against
them arising out of the performance of this Agreement.

 

    	22

     

    

 

12.4
Governing Law. This Agreement shall be construed, and legal relations between the parties hereto shall be determined, in accordance
with the laws of the State of Maryland applicable to contracts solely executed and wholly to be performed within the State of Maryland
without giving effect to the principles of conflicts of laws. Any disputes between the parties to the Agreement shall be brought in the
state or federal courts of Maryland.

 

12.5
Notice. All notices or communication required or permitted to be given by either party hereunder shall be deemed sufficiently given
if mailed by registered mail or certified mail or sent by overnight courier, such as Federal Express, to the other party at its respective
address set forth below or to such other address as one party shall give notice of to the other from time to time hereunder. Mailed notices
shall be deemed received on the third business day following the date of mailing. Notices sent by overnight courier shall be deemed received
the following business day. Notices may be sent by facsimile provided that any notice sent by facsimile is confirmed by registered mail
or certified mail or sent by overnight courier. Notices received by facsimile shall be deemed received on the day either party receives
such a facsimile at the number listed below.

 

	If
    to Licensee:	BriaCell
    Therapeutics Corp.
	 	2929
    Arch Street, 3rd Floor 
	 	Philadelphia, PA 19104
	 	ATTN:
    William V. Williams, M.D.
	 	Email:
    williams@briacell.com

 

	If
    to UMBC:	Director,
    Office of Technology Development
	 	University
    of Maryland, Baltimore County
	 	1000
    Hilltop Circle
	 	Engineering
    bldg. Room 329
	 	 Baltimore, MD 21228
	 	ATTN:
    Wendy Martin
	 	Email:
    wmartin@umbc.edu
	 	410-455-3658

 

12.6
Successors and Assigns. Neither this Agreement nor any of the rights or obligations created herein, except for the right to receive
any remuneration hereunder, may be assigned by either party, in whole or in part, without the prior written consent of the other party,
except that either party shall be free to assign this Agreement in connection with any sale of substantially all of its assets without
the consent of the other. Any such assignment by Licensee shall be subject to UMBC approval, which approval shall not be unreasonably
withheld. This Agreement shall bind and inure to the benefit of the successors and permitted assigns of the parties hereto. Any attempt
to assign this Agreement other than as expressly permitted by this Article shall render the attempted assignment null and void.

 

12.7
Entire Agreement; Amendment. Licensee and UMBC acknowledge that they have read this entire Agreement and that this Agreement, including
the attached Exhibits constitutes the entire understanding and contract between the parties hereto and supersedes any and all prior or
contemporaneous oral or written communications with respect to the subject matter hereof, all of which communications are merged herein.
It is expressly understood and agreed that (i) there being no expectations to the contrary between the parties hereto, no usage of trade,
verbal agreement or another regular practice or method dealing within any industry or between the parties hereto shall be used to modify,
interpret, supplement or alter in any manner the express terms of this Agreement; and (ii) this Agreement shall not be modified, amended
or in any way altered except by an instrument in writing signed by both of the parties hereto.

 

12.8
Force Majeure. If either party fails to fulfill its obligations hereunder (other than an obligation for the payment of money), when
such failure is due to an act of God, or other circumstances beyond its reasonable control, including but not limited to fire, flood,
civil commotion, riot, war (declared and undeclared), revolution, or embargoes, then said failure shall be excused for the duration of
such event and for such a time thereafter as is reasonable to enable the parties to resume performance under this Agreement.

 

12.9
Counterparts. This Agreement may be executed in counterparts, each of which shall be deemed an original and all of which when taken
together shall be deemed but one instrument

 

    	23

     

    

 

IN
WITNESS WHEREOF, the parties have caused this Agreement to be executed by their duly authorized representatives as of the date the last
party hereto has executed this Agreement.

 

	UNIVERSITY
                                            OF MARYLAND, BALTIMORE COUNTY
	 	BriaCell
    Therapeutics Corp.
	 	 	 	 	 
	By:
    	/s/
    Wendy Martin	 	By:
    	/s/
    William V. Williams, M.D.
	 	 	 	 	 
	Wendy
    Martin	 	William
    V. Williams, M.D. 
	Director,
    Office of Technology Development	 	President
    and CEO

 

	Date:
    	August 1, 2022	 	Date:
    	
    July 28, 2022

 

    	24

     

    

 

Exhibit
A

 

Patent
Rights

 

	Invention
                                            Number
	 	Invention
    Title	 	Intellectual
                                            Property Numbers
	 	Inventor(s)
	2649SR	 	Soluble
                                            CD80 as a

                                                         Therapeutic
                                            to

                                                         Reverse
                                            Immune

                                                         Suppression
                                            in Cancer

                                                         Patients
	 	US
                                            13/660,037 issued as US 8,956,619

     

    US
    14/617,090 issued as US 9,650,429

     

    US
    15/492,535 issued as US 10,377,810
	 	Suzanne
    Ostrand- Rosenberg

 

    	25

     

    

 

Exhibit
B

 

Milestones

 

	Milestone	 	Deadline
	Submit
    an IND to FDA (or foreign equivalent) for a Licensed Product	 	3
    years after the Effective Date
	Dosing
    of first patient in a Phase 1 Clinical Trial of a Licensed Product	 	4
    years after the Effective Date
	Obtain
    regulatory approval for marketing a Licensed Product anywhere in the world	 	12
    years after the Effective Date
	Achieve
    First Commercial Sale of a Licensed Product	 	13
    years after the Effective Date

 

    	26

     

    

 

Exhibit
C

 

Business
Plan Synopsis

 

BriaCell
Therapeutics Corp.

2929
Arch Street, 3rd Floor

Philadelphia,
PA 19104

Incorporated
in Delaware

Incorporated
as of January 7, 2022

 

Management
Team:

 

William
V. Williams, MD, FRCP

President
and CEO

 

Gadi
Levin, CA, MBA

CFO
and Corporate Secretary

 

Giuseppe
Del Priore, MD, MPH

Chief
Medical Officer

 

Miguel
A. Lopez-Lago, PhD

Chief
Scientific Officer

 

Business
Description & Opportunity:

 

BriaCell
is a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer. We are developing novel cellular immunotherapies
for cancer in combination with immune checkpoint inhibitors. We currently have an ongoing phase I/II study in advanced breast cancer
with our lead candidate Bria-IMTTM in combination with retifanlimab, Incyte Corporations PD-1 inhibitor. We have seen remarkable
responses in predictable subsets of patients in spite of them having been very heavily pretreated with prior therapies. Or observations
with Bria-IMTTM have led to the development of a platform technology whereby we can personalize our immunotherapy cell lines 4 patients
tailoring them to the patient’s HLA type and thereby enhancing clinical benefit. These immunotherapy cell lines are pre-manufactured
and therefore off the shelf even though they are personalized to the individual patient. In addition to breast cancer we are developing
immunotherapy cell lines for prostate cancer lung cancer and Melanoma and hope to extend to other cancer types in the future.

 

BriaCell
is very interested in licensing the soluble CD80 immunotherapy from the University of Maryland. Our plan would be to complete preclinical
toxicology and pharmacokinetic testing on the soluble CD80 construct over the next year and a half at a cost of approximately $1.5 million.
We would then submit an IND and begin a phase I/II study in patients with advanced cancer. This initially would be a monotherapy study
but later could combine with other agents. Our plan would be to develop the soluble CD80 in combination with our cellular immunotherapies
but also in combination with other therapies for patients with cancer. Our focus at BriaCell is to establish proof of concept partnered
with larger pharmaceutical companies for registration and approval and marketing for our products. However, we also have the capability
to take products through to full approval and marketing. This would require additional capital raise efforts by Briacell which are within
our capabilities.

 

    	27

     

    

 

The
value proposition would be to market our therapies in patients with cancer in collaboration with a large pharmaceutical company. The
market size will depend on the specific indication and the competitive landscape at that time. However, with reasonably good efficacy
and safety data we anticipate market size is in excess of a billion dollars a year in peak sales.

 

Major
Risks: (technical, regulatory, competition, contingency plans if something occurs)

 

Major
technical risks for the soluble CD80 drug candidate include safety and efficacy. CD80 binds to CD28 and activates T cells in addition
to its activity as an immune checkpoint inhibitor. Prior clinical trials with other molecules that bind to CD28 resulted in cytokine
storm which has been life-threatening. We are performing certain in vitro experiments to obviate this risk, but it remains a risk. There
is also a risk that sufficient to see will not be achieved with this molecule. In terms of efficacy, Dr. Ostrand-Rosenberg has performed
a number of animal model studies that look very promising. However, these may or may not directly translate into the human situation.

 

Major
regulatory milestones would include a successful pre-IND meeting with the FDA during 2023, successful filing of an IND in early 2024,
achievement of fast track status in 2024, a successful end of phase two meeting with approval of a pivotal study design in 2025, and
of course successful submission and approval of a biological licensing application likely in 2027-2028.

 

In
terms of competition, Alpine Biosciences (https://www.alpineimmunesciences.com/) is developing Davoceticept, a variant CD80 extracellular
domain, engineered by directed evolution to bind PD-L1 as well as CD28 and CTLA-4. They showed very promising results at the AACR 2022
meeting. 11 (23%) of 48 evaluable participants demonstrated tumor volume reduction; 26 (54%) achieved clinical benefit as defined as
a best response of stable disease or better; Three (6%) remained on treatment beyond 6 months. Two partial responses were observed in
colorectal and renal cell carcinoma. While this represents a challenge, it also represents an opportunity as there is some prior validation
of this similar technology. Note that immune checkpoint inhibitors are approved in dozens of different types of cancer and in different
settings. We feel there will be plenty of room in the soluble CD80 landscape for different products.

 

Financing:

 

Briacell
has publicly traded on the NASDAQ and has thousands of investors. We have $44.5 million in cash as of our most recent financial statements.
This is sufficient to complete the preclinical Ind enabling studies for soluble CD 80. It is also enough to initiate a phase one study
in 2023. We may be able to obtain additional capital through licensing and or collaborative opportunities with some of our current cellular
immunotherapy. This may be sufficient to continue development of soluble CD80 through proof of concept and beyond. We also have the ability
to raise additional capital and have relationships with various investment banks to help us secure the funding needed.

 

    	28

     

    

 

Exhibit
D

 

Past
Patent Costs

 

	UMBC IP Ref. No.	 	Patent Serial No	 	Invoice Dates	 	Invoice Amounts	 
	2649SR	 	US 13/660,037	 	Through the Effective Date	 	$	32,449.30	 
	 	 	USPN 8,956,619	 		 	 	 	 
	 	 	US 14/617,090	 	 	 	 	 	 
	 	 	USPN 9,650,429	 	 	 	 	 	 
	 	 	US 15/492,535	 	 	 	 	 	 
	 	 	USPN 10,377,810	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 
	 	 	 	 	Subtotal	 	$	32,449.30	 
	 	 	 	 	MII grant	 	$	(10,000	)
	 	 	 	 	Total
Past Patent Costs Owed
	 	$	22,449.30	 

 

    	29Exhibit 10.1

 

 

 

Employment Job Offer/Contract

 

Dear Mr. David Tang,

 

We are pleased to offer you a position at
Genufood Energy Enzymes Corp (GEEC). Your start date, position details, compensation, benefits and other terms of employment are
outlined below.

 

Commencement Date

 

		1.	Your full-time employment with GEEC will begin on 07/15/2022.
You will be engaged in the role of Chief Executive Officer (CEO); directly report to the Board.

 

		2.	As CEO of GEEC, you will be responsible to execute development of EVSE (Electric vehicle supply
                                                                                  equipment or commonly known as charging stations), and coordinate global strategy and marketing.

 

		3.	In the role of Chief Executive Officer (CEO), you will be expected to execute the duties and
                                                                                  responsibilities described in the job description we’ve provided, which is updated periodically to reflect position needs.
                                                                                  Please note that you may be asked to take on other responsibilities as needed by GEEC.

 

		4.	In addition to serving as Chief Executive Officer (CEO) of GEEC,
you will be appointed to serve on Board of Directors, commencing 180 days from signing of this agreement.

 

Place and Time of Work

 

		1.	Your primary place of work will be in Los Angeles, but remotely
until office is deemed necessary. You may be required to work at other locations as reasonably determined by the needs of GEEC.

 

		2.	GEEC’s general hours of business are between 9AM-6PM California
Time. You are expected to work 40 hours per week during general business hours.

 

At-Will Employment

 

		1.	GEEC
and you both acknowledge that your employment is and shall continue to be at-will, as defined under applicable law. If the Employee’s
employment terminates for any reason, the Employee shall not be entitled to any payments, benefits, damages, awards or compensation other
than as provided by this Agreement and Stock Option Agreement, or as may otherwise be established under the Company’s then existing
employee benefit plans or policies at the time of termination.

 

		2.	If you wish to terminate your employment with GEEC, a 4-week
notice is required

  

Compensation

 

		1.	Your total compensation of $150,000 includes 3 parts: Base Salary,
Bonus, and Stock Option.

 

		a.	Base Salary: The annual Base Salary for this position is USD $150,000.

 

		b.	Bonus: Your annual bonus is subject to mutually agreed milestones
with Board of GEEC. You will first be eligible for a bonus in March 2023 for your performance in 2022.

 

		c.	Stock Option In Lieu of Reduced Base Salary: You agree that in exchange for reduction in Base Salary,
                                                                                 you will be awarded stock option incentive plan, effective immediately upon signing of this agreement. You are eligible
                                                                                 for no less than 15,000,000 shares of GEEC Stock Option with one year cliff and 4 year vesting schedule. All grants or
                                                                                 awards shall be governed by the relevant plan documents and requirements and shall be evidenced by the Company’s stock option,
                                                                                 restricted stock or other applicable agreement.

 

		2.	The company payment at the 1th of the month for the
prior month base salary.

 

    1 / 3

     

    

 

 

 

Employee Benefits

 

		●	You
will be eligible for the same employee benefit plans such as medical/dental insurance and telecommunication/commuting reimbursements
as other US-based full-time employees.

 

Reimbursement of Expenses

 

		●	You
will be reimbursed for all reasonable and necessary expenses paid for or incurred by you in the performance of your job duties. You will
be required to provide GEEC with all original receipts for such expenses.

 

Paid Time Off

 

		1.	You are entitled 15 PTO (Paid Time Off) each year after you
complete 90 days of the services. The policy is on monthly accrued base.

 

		2.	You’re entitled to sick days in accordance with Company
policy.

 

		3.	The PTO is carryover policy, capped at 200 hours at the end
of year.

 

		4.	Day off request need to be submitted to the Board at least 3
days in advance.

 

		5.	Upon termination of employment, GEEC will pay your unused PTO.

 

Performance Reviews

 

		●	You
will be provided with a performance review every six months to ensure your performance is in line with your position. This review will
provide feedback on your strengths as well as areas for improvement.

  

Confidentiality of Information

 

		1.	During your employment, you’ll likely become aware of
information relating to the business of GEEC, including pricing structures, client details, client lists, etc.

 

		2.	All confidential information and all documents created by you
during your employment are the property of GEEC. You shall not directly or indirectly divulge confidential information to any person
for your own or another person’s benefit.

 

Nondisclosure Agreement

 

		●	As
a condition of your employment, you agree to sign GEEC’s standard Nondisclosure Agreement. In addition, we do not want you to bring
with you any confidential or proprietary materials from any former employers.

 

Governing and Choice of Law

 

Governing Law; Jurisdiction. This Agreement and the legal relations
thus created between the parties hereto (including, without limitation, any dispute arising out of or related to this Agreement) shall
be governed by and construed under and in accordance with the internal laws of the State of California, without reference to its principles
of conflict of laws.

 

Choice of Law. All issues and questions concerning the construction,
validity, enforcement, and interpretation of this Agreement shall be governed by, and construed in accordance with, the laws of the State
of California, without giving effect to any choice of law or conflict of law rules or provisions that could cause the applications of
the laws of any jurisdiction other than the State of California.

 

    2 / 3

     

    

 

 

 

We also here recognize that you have commenced your duty as CEO beginning
July 15, 2022, and that this offer letter is signed after above date.

 

Please signify your acceptance of these employment conditions by signing
and dating this letter and returning them to Jui-Pin (John) Lin by no later than 7/28/2022.

 

Should you have any questions, please do not hesitate to contact John
J.P Lin at john.lin@geecenzymes.com

 

Sincerely, 

Jui-Pin (John) Lin 

Chairman of board of Genufood Energy Enzymes Corp. 

 

	/s/ David
    Tang	 	Date:	 July 29, 2022
	(Employee signature)	 	 	 

 

	David Tang	 
	(Printed name of employee)	 

 

	/s/ Jui-Pin (John) Lin	 	Date:	29, July, 2022
	(Employer representative signature)	 	 	 

 

	Jui-Pin (John) Lin	 
	(Printed name of employer representative)	 

 

 

3 / 3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00347-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00347-of-00352.parquet"}]]